Role of flavonoids in management of various biological targets in Alzheimer’s disease: evidence from preclinical to clinical studies

More than 10 million people worldwide have Alzheimer's disease (AD), a de-generative neurological illness and the most prevalent form of dementia. AD's progression in memory loss, cognitive deterioration, and behavioral changes are all symptoms. Amyloid-beta 42 (Aβ42), the hyperphosphorylated forms of microtubule-associated tau protein, and other cellular and systemic alterations are all factors that contribute to cognitive decline in AD. Rather than delivering a possible cure, present therapy strategies fo-cus on reducing disease symptoms. It has long been suggested that various naturally oc-curring small molecules (plant extract products and microbiological isolates, for exam-ple) could be beneficial in preventing or treating disease. Small compounds, such as flavonoids, have attracted much interest recently due to their potential to alleviate cellular stress. Flavonoids have been proven helpful in various ways, including antioxidants, anti-inflammatory agents, and anti-apoptotic agents, but their mechanism remains un-known. The flavonoid therapy of Alzheimer's disease focuses on this review, which in-cludes a comprehensive literature analysis.